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Abstract
We evaluated a cocktail of HLA-A2-specific peptides including heteroclitic XBP1 US184-192 
(YISPWILAV), heteroclitic XBP1 SP367-375 (YLFPQLISV), native CD138260-268 (GLVGLIFAV) 
and native CS1239-247 (SLFVLGLFL), for their ability to elicit multipeptide specific cytotoxic T 
lymphocytes (MP-CTL) using T cells from smoldering multiple myeloma (SMM) patients. Our 
results demonstrate that MP-CTL generated from SMM patients’ T cells show effective anti-MM 
responses including CD137 (4-1BB) upregulation, CTL proliferation, IFN-γ production, and 
degranulation (CD107a) in an HLA-A2-restricted and peptide-specific manner. Phenotypically, 
we observed increased total CD3+CD8+ T cells (>80%) and cellular activation (CD69+) within the 
memory SMM MP-CTL (CD45RO+/CD3+CD8+) subset after repeated multipeptide stimulation. 
Importantly, SMM patients could be categorized into distinct groups by their level of MP-CTL 
expansion and anti-tumor activity. In high responders, the effector memory 
(CCR7-CD45RO+/CD3+CD8+) T cell subset was enriched, while the remaining responders’ CTL 
contained a higher frequency of the terminal effector (CCR7-CD45RO-/CD3+CD8+) subset. These 
results suggest that this multipeptide cocktail has the potential to induce effective and durable 
memory MP-CTL in SMM patients. Therefore, our findings provide the rationale for clinical 
evaluation of a therapeutic vaccine to prevent or delay progression of SMM to active disease.
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INTRODUCTION
Smoldering myeloma (SMM) is a precursor to multiple myeloma (MM) in which the patient 
does not display any of the typical myeloma-related symptoms, such as elevated calcium 
levels, kidney damage, anemia or bone lesions.1,2 Early treatment strategies for SMM are 
particularly attractive, since the rate of progression to MM is substantially greater (10%) as 
compared to monoclonal gammopathy of undetermined significance (MGUS, 1%). 
Currently, the standard of care for most SMM patients remains vigilant observation while 
withholding standard therapy, due to chemotherapy-related toxicity and the challenge of 
identifying high-risk SMM patients at diagnosis.3-5 There have been several clinical trials to 
treat SMM patients; however, no significant clinical benefits have been observed with 
different therapeutic options including melphalan-prednisone, zoledronic acid or 
thalidomide and pamidronate, either in a single-arm trial or randomized-controlled trials.6-8
Recent findings indicate that development of active MM from asymptomatic precursor states 
is associated with worsening immune dysfunction. Defects in T-cell function, including loss 
of tumor-specific effector T cell activity and induction of Treg cells, along with cytokines 
and growth factors including interleukin-6 (IL-6), macrophage inflammatory protein 
(MIP)-1α, insulin-like growth factor (IGF)-I, VEGF, and hepatocyte growth factor (HGF), 
contribute to myeloma pathogenesis.9,10 The expression of PD-L1, which is detected on 
MM cells but not in healthy donors, may also be associated with reduced susceptibility to 
tumor cell lysis by CTL.11,12 MM has the unique ability to elude immunosurveillance 
through various mechanisms including reduced T-cell cytotoxic activity, induction of 
dendritic cell dysfunction, expansion of myeloid-derived suppressor cells, decreased 
responsiveness to IL-2, and defects in B-cell immunity.13-15 These immune defects 
associated with MM pathogenesis account at least in part, for the failure of recent 
immunotherapy trials in patients with MM.16 Thus, we hypothesize that early 
immunotherapeutic intervention in SMM patients with retained immune function may offer 
an opportunity to prevent or delay disease progression to active MM.
Antigen-specific cancer vaccines targeting various tumor-associated antigens (TAA) have 
been shown to elicit tumor-suppressive responses in the clinical setting. A large number of 
clinical trials have been carried out using different TAA with minimal toxicities and side 
effects.17, 18 XBP1 (X-box binding protein 1), CD138 (Syndecan-1) and CS1 (CD2 subset 1, 
CRACC, SLAMF7, CD319) antigens are highly expressed on MM with therapeutic 
potential, as demonstrated in preclinical and clinical studies.19-24 In previous studies, we 
identified immunogenic HLA-A2-specific peptides derived from each of these target 
antigens including heteroclitic XBP1 unspliced (US)184-192 (YISPWILAV),25 heteroclitic 
XBP1 spliced (SP)367-375 (YLFPQLISV),25 native CD138260-268 (GLVGLIFAV)26, and 
native CS1239-247 (SLFVLGLFL)27 peptides. These selected immunogenic peptides, either 
individually or combined as a four-peptide cocktail, induced antigen-specific CTL with 
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functional activities against HLA-A2+ MM cells.21,25-27 Expanding on our previous studies, 
we demonstrate here that these HLA-A2-specific XBP1 US, XBP1 SP, CD138 and CS1 
peptides are highly immunogenic to SMM patients’ T cells and induce highly effective anti-
MM immunity. The capacity for SMM patients’ T cells to respond to each of these peptides 
and trigger expansion of CD3+CD8+ CTL with functional activities against the respective 
epitopes on MM cells provides the framework for clinical evaluation of vaccination with 
these peptides in patients with SMM to prevent progression to active disease.
MATERIALS AND METHODS
Cell lines
MM cell lines including HLA-A2+ McCAR, HLA-A2+ U266, HLA-A2- MM1S, and HLA-
A2- RPMI along with the chronic myelogenous leukemia (CML) K562 cell line, were 
obtained from the ATCC. The K562 cell line transduced with HLA-A*0201 cDNA (K562-
A*0201) was provided by Dr. P. Cresswell (Yale University). The T2 cell line, a human B 
and T cell hybrid expressing HLA-A2 molecules, was provided by Dr. J. Molldrem 
(University of Texas M. D. Anderson Cancer Center). All cell lines were cultured in 
RPMI-1640 medium (Gibco-Life Technologies) supplemented with 10% fetal calf serum 
(FCS; BioWhittaker), 100 IU/ml penicillin, and 100 μg/ml streptomycin (Gibco-Life 
Technologies).
Synthetic peptides
Heteroclitic XBP1 US184-192 (YISPWILAV), heteroclitic XBP1 SP367-375 (YLFPQLISV), 
native CD138260-268 (GLVGLIFAV), and native CS1239-247 (SLFVLGLFL), along with an 
HLA-A2-specific control MAGE3271-279 (FLWGPRALV) peptide, were synthesized by 
standard fmoc (9-fluorenylmethyl-oxycarbonyl) chemistry, purified to >90% using reverse-
phase chromatography, and validated by mass-spectrometry for molecular weight 
(Biosynthesis). Lyophilized peptides were dissolved in DMSO (Sigma), diluted in AIM-V 
medium (Gibco-Life Technologies), and stored at -140°C.
SMM patient samples
Heparinized venous blood samples were collected from SMM patients after informed 
consent, in accordance with the Declaration of Helsinki and approval by the institutional 
review board at Dana-Farber Cancer Institute (Boston, MA). Clinical characteristics of the 
SMM patients are shown in Table 1.
Peripheral blood mononuclear cell isolation and generation of monocyte-derived dendritic 
cells
Peripheral blood mononuclear cells (PBMC) were isolated by standard density gradient 
centrifugation over Ficoll-Paque™ Plus (Amersham Pharmacia Biotech AB) from the blood 
obtained from HLA-A2+ SMM patients. Dendritic cells (DC) generated from autologous 
adherent monocytes were used as antigen-presenting cells (APCs).25,28
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Isolation of CD3+ T cells from non-adherent cells of SMM patients
SMM patients’ CD3+ T cells were obtained by negative selection from the non-adherent cell 
fraction post-monocyte adherence using the EasySep® magnet and Robosep® (StemCell 
Technologies). The enriched CD3+ T cells (>99% purity) were used to generate MP-CTL.
Induction of MP-CTL generated from SMM patients’ T lymphoctyes
MP-CTL were generated ex vivo by repeated stimulation of CD3+ T lymphocytes obtained 
from HLA-A2+ SMM patients with a cocktail of heteroclitic XBP1 US184-192 
(YISPWILAV), heteroclitic XBP1 SP367-375 (YLFPQLISV), native CD138260-268 
(GLVGLIFAV), and native CS1239-247 (SLFVLGLFL) peptides. In brief, APCs (autologous 
mature DC, T2 cells) pulsed overnight with a cocktail containing the four peptides (25 μg/ml 
total; 6.25 μg/ml/peptide) were irradiated at 20 Gy and then used to stimulate autologous 
CD3+ T cells at a 1:20 APCs-to-CD3+ T cell ratio in AIM-V medium supplemented with 
10% human AB serum. T cell cultures were restimulated every seven days with irradiated 
APCs pulsed with the multipeptide cocktail. IL-2 (50 units/ml) was added to the cultures 
two days after the second stimulation, and was replenished weekly until the cultures were 
completed.
Phenotypic analysis of SMM MP-CTL
One week after the last stimulation, MP-CTL and control T cells were harvested, washed in 
FACS buffer, and incubated with fluorochrome conjugated anti-human monoclonal 
antibodies (mAb) (BD Biosciences). After staining, the cells were washed, fixed in 2% 
paraformaldehyde-PBS, and analyzed by flow cytometry.
SMM MP-CTL proliferation in response to MM cell lines
To measure proliferation, SMM MP-CTL were labeled with CFSE (Molecular Probes), 
washed extensively, and co-incubated with irradiated (20 Gy) HLA-A2+ or HLA-A2- MM 
cell lines or control K562 cells in the presence of IL-2 (10 units/ml). As a control, CFSE-
labeled SMM MP-CTL were cultured in media alone with IL-2. On days 5-7, cells were 
harvested and stained with anti-CD3/CD8 mAbs; the level of cell proliferation was 
evaluated by flow cytometry.
SMM MP-CTL degranulation and intracellular IFN-γ production in response to MM cells
CD107a degranulation and IFN-γ producing CD3+CD8+ T cells were identified within 
SMM MP-CTL by flow cytometry. Briefly, SMM MP-CTL were stimulated with HLA-A2+ 
or HLA-A2- MM cell lines, K562 cells, K562-A*0201 cells pulsed with respective peptide 
or K562-A*0201 cells alone in the presence of CD107a anti-human mAb. SMM MP-CTL 
alone served as a negative control. After 1 hour incubation, CD28/CD49d mAb (BD), as 
well as protein transport inhibitors Brefeldin A and Monensin (BD), were added for an 
additional 5 hours. Cells were harvested, washed in FACS buffer, and incubated with mAbs 
specific to CD3, CD8, CCR7, CD45RO, CD69 and/or CD137 antigens. After surface 
staining, cells were washed, fixed/permeabilized, stained with anti-IFN-γ mAb (BD), 
washed with Perm/Wash solution (BD), fixed in 2% paraformaldehyde, and analyzed by 
flow cytometry.
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Analysis of SMM MP-CTL post-lenalidomide treatment
One week after the fourth stimulation, SMM MP-CTL were harvested and treated with 
Lenalidomide (5 μm, Celgene). Following an additional 4 days incubation, MP-CTL were 
evaluated for CD107a upregulation and IFN-γ production upon stimulation with MM cells, 
as described above. In addition, MP-CTL were evaluated for their phenotype by staining 
with mAbs specific to CD3, CD8, CD28 and/or CD137 antigens. The cells were washed, 
fixed in 2% paraformaldehyde, and analyzed by flow cytometry.
Statistical Analysis
Results are presented as mean ± SE. Groups were compared using unpaired Student’s t-test. 
Differences were considered significant when *p < 0.05.
RESULTS
A cocktail of HLA-2 specific XBP1 US/XBP1 SP/CD138/CS1 peptides effectively induces 
and expands CD3+CD8+ CTL from T cells of SMM patients, and the MP-CTL demonstrate 
HLA-A2 restricted cell proliferation in response to MM cell lines
A cocktail of HLA-A2 specific XBP1 unspliced, XBP1 spliced, CD138, and CS1 peptides 
was evaluated for its ability to induce antigen-specific CTL from enriched CD3+ T cells of 
SMM patients (n=4). One week after the first, third, and fourth MP-cocktail stimulation, 
cultures were evaluated for frequency of CD3+CD8+ T cells and CD3+CD4+ T cells by flow 
cytometry. An increase in the proportion of CD3+CD8+ T cells (Supplemental Figure 1A) 
and a corresponding decrease in CD3+CD4+ T cells (Supplemental Figure 1B) were detected 
following each round of multipeptide stimulation. The highest level of CD3+CD8+ (> 80%) 
and lowest level of CD3+CD4+ (< 20%) T cells were reached following the fourth 
stimulation (Figures 1A, 1B). These results demonstrate that stimulation with XBP1 US/
XBP1 SP/CD138/CS1 multipeptide induces and expands CD3+CD8+ CTL from T cells of 
SMM patients.
Cell proliferation was measured, one week after the fourth peptides stimulation, by the 
decrease in fluorescence intensity (P3 gate) of CFSE labeled cells upon incubation with 
tumor cells. MP-CTL generated from SMM patient #1 (Figure 1A) showed increased 
CD3+CD8+ T cell proliferation on days 5 (13.6%), 6 (46.2%), and 7 (80.7%) in response to 
HLA-A2+ MM cells (McCAR). Similarly, MP-CTL from SMM patient #2 (Figure 1B) 
showed increased cell proliferation, starting on day 5 (30.6%) and peaking at day 7 (75.6%) 
in response to McCAR cells. However, the SMM MP-CTL did not proliferate to HLA-A2- 
MM cells (MM1S, RPMI) or NK-sensitive K562 cells (Figures 1A, 1B), thereby 
demonstrating HLA-A2-restricted cell proliferation.
Multipeptide-CTL generated from SMM patients demonstrate HLA-A2 restricted IFN-γ 
production and CD107a degranulation in response to MM cell lines
We further analyzed SMM MP-CTL for their functional anti-MM activities, including IFN-γ 
production and CD107a degranulation, following incubation with various MM cell lines or 
K562 cells. Representative flow cytometric analyses demonstrate that SMM MP-CTL had 
specific IFN-γ production (Figure 2A) against HLA-A2+ MM cells (McCAR), but not 
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against HLA-A2- MM cells (MM1S, RPMI) or K562 cells. These observations were 
confirmed in further analyses of MP-CTL generated from additional HLA-A2+ SMM 
patients (n=4), which displayed IFN-γ production (Figure 2B) in an HLA-A2-restricted 
manner, and were not mediated by NK cells.
Next, further flow cytometric analyses demonstrate that the SMM MP-CTL had specific 
CD107a upregulation (Figure 3A) against HLA-A2+ MM cells (McCAR, U266), but not 
against HLA-A2- MM cells (MM1S, RPMI) or K562 cells. The MP-CTL generated from 
other HLA-A2+ SMM patients (n=4) displayed the same pattern of response in CD107a 
degranulation (Figure 3B) in an HLA-A2-restricted manner without NK cell activity. 
Interestingly, we detected higher levels of these anti-tumor activities against either HLA-
A2+ MM cell line by MP-CTL generated from SMM patients #2 and #4 as compared to 
SMM patients #1 and #3 (Figures 2B, 3B).
Multipeptide-CTL from SMM “high” responders are distinct in phenotype and functional 
activities against MM cells
SMM MP-CTL (n=8) were evaluated for total CD3+CD8+ T cells, naïve:memory 
phenotypes and immune function. Results demonstrate that frequencies of CD3+CD8+ T 
cells in the MP-CTL generated from eight individual SMM patients were similar after four 
rounds of multipeptide stimulation (Figure 4A). However, total MP-CTL yields were 
distinctively higher from SMM patients #2 and #4 (1.2–1.3×109 cells) as compared to those 
from the remaining six SMM patients (6–15×106 cells). In addition, the highest level of 
IFN-γ production and CD107a degranulation in response to target cells (HLA-A2+ U266) 
was from MP-CTL generated from SMM patients #2 and #4, as compared to those from the 
other SMM patients (Figure 4A).
Next, we evaluated MP-CTL from the SMM “high” responders (patients #2 and #4) and two 
SMM “normal” responders (patients #1 and #3) for their naïve:memory phenotypic profile. 
CD3+CD8+ T lymphocytes responding to an antigen differentiate from naïve to antigen-
specific CTL with various effector and memory functions.29,30 In these studies, SMM MP-
CTL contained mainly effector memory (EM; CD45RO+CCR7-) and terminal effector (TE; 
CD45RO-CCR7-) along with a low frequency (<5%) of naïve (CD45RO-CCR7+) and 
central memory (CM; CD45RO+CCR7+) CD3+CD8+ T cells (Figure 4B). Importantly, a 
higher frequency of EM cells was detected in the MP-CTL from “high” responders (SMM 
#2: 66.4%, SMM #4: 66.5%) as compared to the “normal” responders (SMM #1: 20.5%, 
SMM #3: 45.3%). In contrast, a higher level of differentiated TE subset was seen in the 
“normal” responders as compared to the “high” responders.
Based on these observations, we continued to culture the MP-CTL from the “high” 
responders for 7 weeks with weekly MP-cocktail stimulation. Overall, we observed 
increased frequency of the EM subset in MP-CTL after 7 stimulations (SMM #2: 79.1%, 
SMM #4: 92.2%), without further differentiation into TE subset (Figure 4C). These results 
suggest that maintenance of an EM CTL subset might be critical for a long-term anti-tumor 
response, and may serve as a valuable biomarker when defining the efficacy of the 
multipeptide vaccine in future clinical studies.
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Multipeptide-CTL generated from SMM patients include a high proportion of EM subset 
producing IFN-γ and expressing CD107a in response to MM cells with the highest levels 
detected in MP-CTL from SMM “high” responders
Next, we investigated the level of specific immune activity within different CD3+CD8+ T 
cell naïve:memory subsets of SMM MP-CTL in response to MM cells. Results (“% Total 
Adjusted”) were calculated as the percent contribution of each specific subset to total IFN-γ 
production or CD107a degranulation. The highest IFN-γ production was detected in the EM 
subset (67.25±16.88%), followed by TE (20.25±5.11), CM (8.25±3.15) and naïve (4.0±1.78) 
subsets, in response to HLA-A2+ McCAR or U266 MM cells (Figure 5A). A similar pattern 
of immune activity was observed for CD107a degranulation in the SMM MP-CTL (EM 
69.50±6.36, TE 21.00±3.54, CM 7.50±3.43, naïve 1.50±1.19) to the HLA-A2+ MM cells 
(Figure 5B). In addition, the EM subset had a higher level of single response, IFN-γ 
production and CD107a degranulation, as compared to the TE subset (Figures 5A, 5B). We 
also observed that the highest proportion of dual functional cells (IFN-γ+/CD107a+) were 
from MP-CTL of a SMM “high” responder (patient #2) as compared to those of “normal” 
responders (patients #1 and #3) (Figure 5C). The dual functional activities were confirmed 
as HLA-A2-restricted in either EM or TE subsets of SMM MP-CTL.
Finally, we analyzed the level of MM specific cellular activation (% CD69+ cells) within the 
CD3+CD8+ naïve:memory subsets of SMM MP-CTL. Cellular activation was higher in the 
CD45RO+ memory cell subset as compared to the CCR7+CD45RO- naïve cell counterpart 
(Supplemental Figure 2). MM-specific cell activation was detected in response to HLA-A2+ 
McCAR or U266 MM cells, but not to HLA-A2- MM1S or RPMI MM cells (Supplemental 
Figure 3). However, unlike the IFN-γ production and CD107a degranulation, the level of 
CD69 upregulation could not be used to classify SMM MP-CTL as “high” or “normal” 
SMM responders.
Multipeptide-specific CTL induced from SMM patients demonstrate both IFN-γ production 
and CD107a degranulation in response to each relevant peptide
SMM MP-CTL were further examined for their ability to specifically recognize and respond 
to each relevant peptide contained within the MP-cocktail. In these assays, we analyzed 
individual peptide-specific responses in the activation-induced CD137+CD3+CD8+ T cell 
population.31 A representative flow cytometric analysis demonstrates both IFN-γ production 
and CD107a degranulation by SMM MP-CTL in response to K562-A*0201 cells pulsed 
with the relevant peptide including heteroclitic XBP1 US184-192 (YISPWILAV), heteroclitic 
XBP1 SP367-375 (YLFPQLISV), native CD138260-268 (GLVGLIFAV), and native 
CS1239-247 (SLFVLGLFL) peptide, but not to cells pulsed with an irrelevant HLA-A2 
specific MAGE-3271-279 (FLWGPRALV) peptide or cells alone pulsed with no peptide 
(Figure 6A). In addition, relevant peptide-specific responses were detected in SMM MP-
CTL (n=3) for both IFN-γ production and CD107a degranulation (Figure 6B). However, 
there were differences in the magnitude of IFN-γ production and CD107a degranulation in 
response to each relevant peptide among the MP-CTL from different SMM patients. 
Overall, SMM MP-CTL (n=3) displayed the highest level of total IFN-γ production or 
CD107a degranulation against native CD138260-268 (GLVGLIFAV) followed by heteroclitic 
XBP1 US184-192 (YISPWILAV), native CS1239-247 (SLFVLGLFL), and heteroclitic XBP1 
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SP367-375 (YLFPQLISV) peptides (data not shown). In summary, SMM MP-CTL are 
capable of recognizing each relevant peptide in MP cocktail, and targeting multiple TAAs 
on MM cells.
Lenalidomide increases the expression of CD28 costimulatory molecule on SMM MP-CTL 
and augments their immune activities in response to MM cells
In these studies, we further investigated whether lenalidomide, an immunomodulatory drug, 
can increase cell yield, regulate expression of critical T cell molecules, or enhance immune 
function of SMM MP-CTL against MM cells. Short-term treatment of MP-CTL with 
lenalidomide (4 days, 5 uM) did not change the overall percentage of total CD3+CD8+ T 
cells as compared to the parent non-lenalidomide treated SMM MP-CTL. Lenalidomide 
treatment of SMM MP-CTL (n=4) enhanced their anti-myeloma activities against McCAR 
(Figure 7A) or U266 (Figure 7B) as shown by the “% increase” in IFN-γ production (9-73% 
increase to McCAR, 6-173% to U266), CD107a degranulation (10-20% increase to 
McCAR, 5-95% to U266), CD28 expression (9-20% increase to McCAR, 3-86% to U266) 
and CD137 upregulation (7-26% increase to McCAR, 0-91% to U266) as compared to 
baseline values of non-drug treated MP-CTL. Therefore, these results demonstrate that 
lenalidomide treatment augments immune function of SMM MP-CTL against MM cells, 
suggesting its potential role to enhance the CTL efficacy post vaccination.
DISCUSSION
Design of an immunotherapeutic approach to induce broad CTL responses specific to 
multiple antigens may overcome antigen mutation or deletion by tumor cells or the variation 
or absence of the appropriate T-cell repertoire in the patient. Targeting multiple epitopes on 
MM cells using a multipeptide vaccine approach could allow a more robust immune 
response against tumor cells, as compared to vaccines specific to a single antigen. In these 
studies, we evaluated a cocktail of four immunogenic HLA-A2-specific peptides, 
heteroclitic XBP1 US184-192 (YISPWILAV), heteroclitic XBP1 SP367-375 (YLFPQLISV), 
native CD138260-268 (GLVGLIFAV) and native CS1239-247 (SLFVLGLFL), for its ability to 
evoke anti-MM immunity in T lymphocytes obtained from HLA-A2+ SMM patients. 
Consistent with our previous studies using “healthy” HLA-A2+ donors’ cells,21,25-27 MP-
CTL generated from SMM patients’ cells displayed a gradual increase in CD3+CD8+ T cells 
upon multipeptide stimulation. In addition, the MP-CTL were predominantly CD45RO+ 
memory subset and demonstrated HLA-A2-restricted polyfunctional immune activities 
against MM cells.
Of potential concern during the development of a multipeptide vaccine is epitope dominance 
along with competition among the peptides for specific HLA-A2 molecules, which may 
impair the full spectrum of immune responses against all of the desired antigens. Due to 
these concerns, individual peptides were administered at different injection sites in previous 
multipeptide vaccine trials to avoid the possibility of competition among epitopes.32,33 
However, this requirement might limit feasibility of an immunotherapeutic approach using 
multiple peptides from new antigens. In these studies, we demonstrate strong immune 
responses of SMM MP-CTL against each relevant peptide, suggesting that possible 
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competition for HLA-A2 molecules among the multipeptide did not compromise the 
immunogenicity of peptides with differing affinities. This finding is consistent with our 
previous observations in MP-CTL generated from “healthy” donors’ T cells.21 Taken 
together, we conclude that simultaneous APC pulsing with our cocktail of four XBP1 US/
XBP1 SP/CD138/CS1 peptides did not interfere with either the induction of MP-CTL or 
their functional capabilities, thereby validating our preclinical rationale for use of the 
multipeptide cocktail as an immunotherapeutic approach for SMM patients. This 
observation highlights the benefit for using the MP-cocktail to overcome differences in T-
cell repertoire among individuals, which could result in the lack of peptide-specific CTL 
induction by a single antigen-based vaccine.
Combination therapies involving adjuvants, therapeutic drugs or immune modulators may 
prove critical for the long-term success of cancer vaccines. Among the potential candidates, 
lenalidomide has been shown to enhance immune function and may prove beneficial when 
used in combination with a therapeutic vaccine. In our studies, short-term exposure of MP-
CTL to lenalidomide enhanced MP-CTL function by increasing CD28 expression, IFN-γ 
production, CD107a degranulation, and CD137 up-regulation, which are critical biomarkers 
to detect anti-tumor activity of CTL. These ex vivo results, along with others’ reports, 
support the use of lenalidomide as an effective combination therapy to increase vaccine 
efficacy in patients with MM.34-36
The efficacy of cancer vaccines requires induction of long-term “memory” CD8+ T cells 
with anti-tumor activities, which are critical for continuous control of disease. Optimally, 
cancer vaccine therapies would induce a “memory-like” CD8+ T cell population which can 
self-renew and respond quickly to tumor antigens, while providing effective and persistent 
long-term anti-tumor immunity.37,38 Clinical evidence has shown a correlation between high 
levels of “effector memory CTL (CD45RO+CCR7-/CD3+CD8+)” in tumor infiltrating 
lymphocytes with both the absence of early metastatic invasion and increased overall 
survival in cancer patients.39-42 In these studies, we generated MP-CTL having effective 
anti-MM activities in all HLA-A2+ SMM patients tested (n=8), thereby validating the 
immunogenicity of the XBP1 US/XBP1 SP/CD138/CS1 multipeptide and its potential as a 
vaccine for SMM patients. In addition, we identified a small group (n=2) of SMM MP-CTL, 
we termed as “high” responders, based on their increased levels of cell expansion and 
immune activities against MM cells. The other “normal” SMM MP-CTL (n=6) generated in 
these studies demonstrated characteristic phenotype and functional activities, as seen in our 
previous study using normal healthy donors’ cells to generate the MP-CTL.21 MP-CTL from 
SMM “high” responders demonstrated ~100 times greater CD3+CD8+ T cell expansion and 
increased levels of anti-MM immunity as compared to SMM “normal” responders. 
Importantly, enrichment in effector memory cell subset was detected in the MP-CTL from 
SMM “high” responders, while SMM “normal” responders contained a higher proportion of 
terminal effector subset. Comparison of anti-tumor activities revealed that the effector 
memory subset mediated greater anti-MM immunity than the counterpart terminal effector 
subset. Furthermore, effector memory CTL from SMM “high” responders were 
continuously maintained and expanded following 7 cycles of MP-stimulation, without 
differentiation into terminal effector CTL. Thus, these observations emphasize the potential 
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to effectively induce strong and extended anti-tumor immunity upon MP-stimulation by 
maintaining the “effector memory” CTL in patients.
It has been hypothesized by others that self-renewal could be the basis for the continual 
generation of effector lymphocytes from the memory pool.43,44 Recently, studies have 
revealed dynamic roles for various transcription factors and other factors in effector and 
memory T cells. The transcriptional repressor Bcl6, transcriptional regulators Id2 and Id3, 
Wnt-β-catenin signaling pathway, and the metabolic status of T cells (i.e., fatty acid 
metabolism, mitochondrial functions) are known to be important for effector or memory 
cells generation.45-46 In contrast, high levels of T-bet and Blimp1 favor terminally 
differentiated effector cells. Additionally, sustained Akt activation is reported to evoke a 
transcriptional program that drives differentiation of effector cells and diminishes CTL’ 
potential to survive.47-48 The pathways and differences in hierarchical differentiation 
between “high” and “normal” SMM responders to the peptides present a unique challenge to 
developing optimal vaccine strategies. Our ongoing studies will elucidate the mechanism for 
arresting differentiation of long-lived and antigen-specific memory CTL to facilitate 
development of immunotherapeutic strategies.
In summary, we demonstrate ex vivo that a cocktail of HLA-A2 specific peptides, 
heteroclitic XBP1 US184-192, heteroclitic XBP1 SP367-375, native CD138260-268, and native 
CS1239-247, can elicit MP-CTL with anti-MM immunity from SMM patients’ T cells. These 
data provide evidence for induction of an effective and durable “effector memory” MP-CTL 
with strong anti-tumor activity in a subset of SMM patients (“high” responders). In addition, 
it would be of interest to know the impact of this MP vaccine in patients with symptomatic 
MM to see if there any of the known immune regulatory issues limit the clinical efficacy of 
the vaccine.49-50 Combining adjuvant therapies to enhance immune function in both 
myeloma and SMM will be explored in our future studies. These results provide the 
framework for a clinical trial with our multipeptide vaccination strategy targeting XBP1, 
CD138, and CS1 antigens to delay or prevent progression of SMM to active MM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key Points
• The multipeptide induces anti-myeloma specific T lymphocytes targeting XBP1, 
CD138 and CS1 antigens from smoldering myeloma patients.
• Multipeptide cocktail has an immunotherapeutic potential as a vaccine in 
smoldering myeloma patients to control the disease progression.
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Figure 1. HLA-A2 restricted cell proliferation of SMM MP-CTL against MM cells
One week after the fourth stimulation, SMM MP-CTL (n=2) were evaluated for cell 
proliferation in response to various MM cell lines. MP-CTL proliferation is shown as the 
percent decrease in CFSE expression (P3-gated) on day 5, 6 or 7 of culture. MP-CTL in 
media alone was used to establish background cell proliferation. MP-CTL generated from 
SMM patient #1 (Figure 1A) or SMM patient #2 (Figure 1B) showed HLA-A2 restricted 
cell proliferation on days 5, 6, and 7 in response to HLA-A2+ MM cells (McCAR), but not 
to HLA-A2- MM cells (MM1S, RPMI) or NK-sensitive K562 cells.
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Figure 2. HLA-A2 restricted IFN-γ production by SMM MP-CTL against MM cells
One week after the fourth stimulation, SMM MP-CTL were analyzed for IFN-γ production 
upon stimulation with various MM cell lines. Representative flow cytometric analysis 
demonstrates increased IFN-γ production by SMM MP-CTL in response to HLA-A2+ MM 
cells (McCAR), but not HLA-A2- MM cells (MM1S, RPMI) or NK-sensitive K562 cells 
(Figure 2A). MP-CTL generated from additional HLA-A2+ SMM patients (n=4) confirmed 
HLA-A2-restricted IFN-γ production to MM cells, but not to NK sensitive K562 cells 
(Figure 2B).
Bae et al. Page 18
Leukemia. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Bae et al. Page 19
Leukemia. Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3. HLA-A2 restricted CD107a degranulation by SMM MP-CTL against MM cells
One week after the fourth stimulation, SMM MP-CTL were analyzed for CD107a 
degranulation upon stimulation with various MM cell lines. Representative flow cytometric 
analysis demonstrates increased CD107a degranulation by SMM MP-CTL in response to 
HLA-A2+ MM cells (McCAR, U266), but not HLA-A2- MM cells (MM1S, RPMI) or NK-
sensitive K562 cells (Figure 3A). MP-CTL generated from additional HLA-A2+ SMM 
patients (n=4) confirmed HLA-A2-restricted CD107a degranulation to MM cells, but not to 
NK sensitive K562 cells (Figure 3B).
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Figure 4. Characterization of SMM MP-CTL reveals a subgroup of SMM “high” responders 
with increased cell yield and immune functional activities
SMM MP-CTL (n=8) were analyzed one week after their fourth MP-cocktal stimulation. 
Total cell yield, % CD3+CD8+ T cells, % IFN-γ+ production, and % CD107a+ degranulation 
are shown for all MP-CTL in response to HLA-A2+ U266 MM cells (Figure 4A). A 
subgroup of MP-CTL (n=2) termed SMM “high” responders (#2, #4) displayed higher levels 
of total cell yield, % IFN-γ+ cells and % CD107a+ cells than MP-CTL generated from other 
SMM patients. Representative naïve:memory subsets analyses of SMM “high” and “normal” 
responders are demonstrated (Figure 4B). The percentage of effector memory cells was 
increased in the MP-CTL from SMM “high” responders, while MP-CTL from SMM 
“normal” responders contained a higher percentage of terminal effector cells. The MP-CTL 
from SMM “high” responders were cultured for an additional 3 rounds of weekly MP 
stimulation (total 7 stimulations). Continuous expansion of the effector memory cell subset 
was detected within the MP-CTL from SMM “high” responders (patients #2, #4) without a 
further differentiation into terminal effector cell subset (Figure 4C).
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Figure 5. Characterization of immune function in the naïve:memory cell subsets of SMM MP-
CTL
A and B. The specific immune function of SMM MP-CTL (n=4) was evaluated within the 
naïve:memory CD3+CD8+ T cell subsets in response to MM cells. The proportion (%) of 
each naïve:memory cell subset contribution to total immune activity is expressed as “% 
Total Adjusted”. The highest level of IFN-γ production (Figure 5A) or CD107a 
degranulation (Figure 5B) was detected in the effector memory cell subset, followed by the 
terminal effector, central memory, and naïve cell subsets within the SMM MP-CTL in 
response to HLA-A2+ MM cells. The effector memory cells from SMM “high” responders’ 
MP-CTL demonstrate increased IFN-γ production and CD107a degranulation as compared 
to those from SMM “normal” responders’ MP-CTL.
C. SMM MP-CTL (n=3) stimulated with HLA-A2+ MM cells were analyzed for the % IFN-
γ+/CD107a+ double positive cells within the effector memory or terminal effector cell 
subset. Effector memory cells demonstrated a higher level of both IFN-γ production and 
CD107a degranulation as compared to terminal effector cells. Effector memory cells in MP-
CTL from the SMM “high” responders had the highest % IFN-γ+/CD107a+ cells. The IFN-
γ+/CD107a+ responses in the SMM MP-CTL were HLA-A2 restricted, and the activities 
were not mediated by NK cells.
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Figure 6. Peptide-specific IFN-γ production and CD107a degranulation immune responses by 
SMM MP-CTL
CD3+CD8+CD137+ cells from SMM MP-CTL were evaluated for their peptide-specific 
IFN-γ production or CD107a degranulation in response to individual peptide pulsed K562-
A*0201 cells.
A. Representative flow cytometric analyses of MP-CTL generated from one SMM patient 
demonstrated the peptide-specific IFN-γ production and CD107a degranulation (Q2 gated) 
by CD3+CD8+CD137+ cells in response to HLA-A2-specific heteroclitic XBP1 US184-192, 
heteroclitic XBP1 SP367-375, native CD138260-268, and native CS1239-247 peptide presented 
by K562-A*0201 cells. Baseline level of IFN-γ production and CD107a degranulation was 
established in response to no peptide pulsed or irrelevant HLA-A2-specific MAGE-3271-279 
peptide pulsed K562-A*0201 cells.
B. The peptide-specific immune responses were demonstrated in MP-CTL generated from 
three different SMM patients. The MP-CTL from each individual SMM patient (patient #1, 
patient #2, patient #3) demonstrated a high level of dual immune activities, % IFN-
γ+CD107a+ cells, within the gated CD3+CD8+CD137+ T cell population, in response to 
each relevant HLA-A2-specific XBP1 US, XBP1 SP, CD138 or CS1 peptide, presented by 
K562-A*0201 cells.
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Figure 7. Modulation of CD28 T cell co-stimulatory molecule expression and immune function of 
SMM MP-CTL by treatment with lenalidomide
SMM MP-CTL (n=4) treated with lenalidomide (4 days, 5 uM) were analyzed for total 
CD3+CD8+ T cells, CD28 costimulatory molecule expression, and functional immune 
responses against MM cells. Lenalidomide treatment of SMM MP-CTL increased their anti-
myeloma activities and specific antigen expression. The % increase in CD3+CD8+ T cells 
expressing IFN-γ, CD107a, CD137 or CD28 is shown for a respective SMM MP-CTL as 
compared to baseline values of non-drug treated MP-CTL, in response to McCAR cells 
(Figure 7A) or U266 cells (Figure 7B).
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